<DOC>
	<DOCNO>NCT02716779</DOCNO>
	<brief_summary>This study examine influence ribavirin initial virological response treatment-na誰ve participant chronic hepatitis C , genotype 1 . Participants randomize 1 3 treatment group receive placebo , ribavirin monotherapy 1000 milligram ( mg ) 1200 mg orally daily depend body weight pegylated interferon ( PEG-IFN ) alfa-2a ( Pegasys速 ) 180 microgram ( mcg ) subcutaneously ( SC ) weekly , 6 week . Following initial 6 week , participant receive combination therapy PEG-IFN alfa-2a plus ribavirin ( Copegus速 ) 12 week . If initial virological response 12 week combination therapy , treatment could continue 36 week outside study .</brief_summary>
	<brief_title>Influence Ribavirin Initial Virological Response Treatment Na誰ve Patients With Hepatitis C Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Caucasians , male female age 18 70 year Indication : serological proof chronic hepatitis C infection positive result antiHepatitis C virus ( HCV ) test detectable HCV Ribo Nucleic Acid ( RNA ) serum Proven HCV genotype 1 mean reverse hybridization assay Proven histological infection activity within liver without proven compensate cirrhosis within last 24 month prior start study ( ChildPugh degree A ) Participants without previous antiHCV therapy Known hypersensitivity interferon ribavirin component part Pregnant nursing woman , woman child bear potential without use high effective method contraception . The urine serum pregnancy test visit 0 fertile participant cohabitants participant must show negative result Male partner pregnant woman Infection HCV genotype 2 , 3 , 4 , 5 , 6 Pretreatment interferon and/or ribavirin Immunocompromised participant Treatment systemic antineoplastic immunomodulatoric medication ( include supraphysiological dos steroid radiation therapy ) within last 6 month prior start treatment complete time interval study treatment Chronic hepatitis due hepatitis C virus ( e.g . haemochromatosis , autoimmunohepatitis , metabolic alcoholrelated liver disease ) Decompensated liver cirrhosis liver disease ChildPugh degree B C condition decompensation Signs hepatocellular carcinoma within 2 month prior randomization case cirrhosis transition cirrhosis Ascites esophagus varix bleeding document anamnesis Any medical condition question opinion investigator participant 's enrollment participation trial Hemoglobin &lt; 13 grams/deciliter ( g/dl ) females &lt; 14 g/dl male screen phase Patients increase anemia risk ( e.g . thalassemia , spherocytosis , etc . ) patient would particular medical risk case anemia Diagnosed neutropenia &lt; 1.500/microliter ( mcl ) thrombocytopenia &lt; 90.000/mcl screen phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>